Should I buy or sell iTeos Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iTeos Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ITOS shares. View ITOS analyst ratings or view top-rated stocks .

What is iTeos Therapeutics' stock price target for 2024?

3 equities research analysts have issued 12-month price objectives for iTeos Therapeutics' shares. Their ITOS share price targets range from $29.00 to $44.00. On average, they anticipate the company's stock price to reach $35.33 in the next twelve months. This suggests a possible upside of 256.9% from the stock's current price. View analysts price targets for ITOS or view top-rated stocks among Wall Street analysts .

How have ITOS shares performed in 2023?

iTeos Therapeutics' stock was trading at $19.53 at the beginning of 2023. Since then, ITOS stock has decreased by 49.3% and is now trading at $9.90. View the best growth stocks for 2023 here .

Are investors shorting iTeos Therapeutics?

iTeos Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 1,590,000 shares, a decrease of 9.1% from the October 31st total of 1,750,000 shares. Based on an average trading volume of 431,100 shares, the short-interest ratio is presently 3.7 days. Currently, 5.6% of the company's shares are sold short. View iTeos Therapeutics' Short Interest .

When is iTeos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our ITOS earnings forecast .

How were iTeos Therapeutics' earnings last quarter?

iTeos Therapeutics, Inc. (NASDAQ:ITOS) posted its earnings results on Tuesday, November, 7th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.20) by $0.30. iTeos Therapeutics had a net margin of 9.02% and a negative trailing twelve-month return on equity of 9.72%.

What ETFs hold iTeos Therapeutics' stock?

ETFs with the largest weight of iTeos Therapeutics (NASDAQ:ITOS) stock in their portfolio include Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and Range Cancer Therapeutics ETF (CNCR) . Virtus LifeSci Biotech Clinical Trials ETF (BBC) .

What other stocks do shareholders of iTeos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iTeos Therapeutics investors own include Advanced Micro Devices (AMD) , GW Pharmaceuticals (GWPH) , Trevena (TRVN) , Blink Charging (BLNK) , Chegg (CHGG) , Centene (CNC) , Datadog (DDOG) , Global Blood Therapeutics (GBT) and Genocea Biosciences (GNCA) .

When did iTeos Therapeutics IPO?

(ITOS) raised $151 million in an IPO on Friday, July 24th 2020. The company issued 8,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are iTeos Therapeutics' major shareholders?

iTeos Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include 683 Capital Management LLC (2.26%), Deerfield Management Company L.P. Series C (2.02%), Jacobs Levy Equity Management Inc. (1.28%), Barclays PLC (0.90%), Bank of New York Mellon Corp (0.78%) and Northern Trust Corp (0.77%). Insiders that own company stock include Aaron I Davis, Ansbert Gadicke , Bioventures 2014 LP Mpm, Bioventures 2018 LP Mpm, Boxer Capital, Llc, David Hallal , Detlev Biniszkiewicz , Joanne Jenkins Lager , Les B Korsh , Matthew Gall , Michel Detheux and Yvonne Mcgrath . View institutional ownership trends .

How do I buy shares of iTeos Therapeutics?

Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

iTeos Therapeutics Stock Price, News & Analysis (NASDAQ:ITOS)

$9.90

+0.54 (+5.77%)

(As of 12/1/2023 ET)

Compare

Today's Range: $8.95
▼
$9.91
50-Day Range: $8.58
▼
$11.51
52-Week Range: $8.20
▼
$23.00

Volume: 341,252 shs
Average Volume: 357,686 shs
Market Capitalization: $354.22 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $35.33

iTeos Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 256.9% Upside
$35.33 Price Target
Short Interest: Healthy
5.57% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.92
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$41,850 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.07) to ($5.43) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.58 out of 5 stars

Medical Sector

124th out of 949 stocks

Biological Products, Except Diagnostic Industry

16th out of 161 stocks

3.5

Analyst's Opinion

Consensus Rating
iTeos Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $35.33, iTeos Therapeutics has a forecasted upside of 256.9% from its current price of $9.90.
Amount of Analyst Coverage
iTeos Therapeutics has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
5.57% of the float of iTeos Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
iTeos Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in iTeos Therapeutics has recently decreased by 9.14%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
iTeos Therapeutics does not currently pay a dividend.
Dividend Growth
iTeos Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ITOS.

3.3

News and Social Media Coverage

News Sentiment
iTeos Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for iTeos Therapeutics this week, compared to 1 article on an average week.
Search Interest
18 people have searched for ITOS on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added iTeos Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, iTeos Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $41,850.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
10.20% of the stock of iTeos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
97.16% of the stock of iTeos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for iTeos Therapeutics are expected to decrease in the coming year, from ($3.07) to ($5.43) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of iTeos Therapeutics is -5.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of iTeos Therapeutics is -5.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
iTeos Therapeutics has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About iTeos Therapeutics Stock (NASDAQ:ITOS)

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

ITOS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ITOS Stock News Headlines

November 29, 2023 | fool.com

iTeos Therapeutics (NASDAQ: ITOS)

November 27, 2023 | finance.yahoo.com

Does iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect?

December 1, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 21, 2023 | finance.yahoo.com

iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference

November 14, 2023 | markets.businessinsider.com

iTeos Therapeutics’ Anticipated Growth and Clinical Updates Drive Buy Rating: An Analyst’s Perspective

November 13, 2023 | finance.yahoo.com

Here's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom Fisher

November 10, 2023 | finance.yahoo.com

Wall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should Know

November 10, 2023 | finance.yahoo.com

Wall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should Know

December 1, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

November 9, 2023 | markets.businessinsider.com

Positive Financial Results and Promising Cancer Treatment Programs Underpin Buy Rating for iTeos Therapeutics

November 7, 2023 | finance.yahoo.com

iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates

October 31, 2023 | finance.yahoo.com

Viridian Therapeutics, Inc. (VRDN) Stock Jumps 5.2%: Will It Continue to Soar?

October 19, 2023 | msn.com

Wedbush Reiterates ITeos Therapeutics (ITOS) Outperform Recommendation

October 16, 2023 | finance.yahoo.com

iTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar?

October 12, 2023 | finanznachrichten.de

S&P Dow Jones Indices: NCR Atleos Set to Join S&P SmallCap 600

September 6, 2023 | finance.yahoo.com

iTeos to Participate in Upcoming Investor Conferences

August 27, 2023 | finance.yahoo.com

BOXER CAPITAL, LLC Reduces Stake in ITeos Therapeutics Inc

August 25, 2023 | seekingalpha.com

iTeos Therapeutics And The TIGIT Ticket To Cancer's Downfall

August 23, 2023 | bizjournals.com

Watertown biotech shares spike after accidental data publication at Roche

August 23, 2023 | markets.businessinsider.com

Why ITeos Therapeutics (ITOS) Stock Is Moving Higher

August 23, 2023 | finance.yahoo.com

Why Roche's Accidental Cancer Update Boosted Iteos 41% And Arcus 28%

August 9, 2023 | msn.com

HC Wainwright & Co. Maintains ITeos Therapeutics (ITOS) Buy Recommendation

August 9, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on iTeos Therapeutics (ITOS)

August 8, 2023 | finanznachrichten.de

iTeos Therapeutics Inc.: iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates

August 8, 2023 | finance.yahoo.com

iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates

June 4, 2023 | seekingalpha.com

iTeos Therapeutics: Trading Under Cash Value

May 13, 2023 | finance.yahoo.com

Broker Revenue Forecasts For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Are Surging Higher

See More Headlines

Receive ITOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/01/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/20/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ITOS
CUSIP: N/A
CIK: 1808865
Web: www.iteostherapeutics.com
Phone: 339-217-0161
Fax: N/A
Employees: 125
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $35.33
High Stock Price Target: $44.00
Low Stock Price Target: $29.00
Potential Upside/Downside: +256.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.73)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $96.65 million
Net Margins: 9.02%
Pretax Margin: -87.36%
Return on Equity: -9.72%
Return on Assets: -8.61%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 21.94
Quick Ratio: 21.94

Sales & Book Value

Annual Sales: $267.63 million
Price / Sales: 1.32
Cash Flow: $2.75 per share
Price / Cash Flow: 3.60
Book Value: $16.72 per share
Price / Book: 0.59

Miscellaneous

Outstanding Shares: 35,780,000
Free Float: 32,135,000
Market Cap: $354.22 million
Optionable: Not Optionable
Beta: 1.23

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Michel Detheux Ph.D. (Age 57)
President, CEO & Director
Comp: $922.38k
Mr. Matthew A. Call M.B.A. (Age 50)
Chief Operating Officer
Comp: $638.55k
Mr. Matthew Gall (Age 46)
Chief Financial Officer
Comp: $628.45k
Dr. Yvonne McGrath Ph.D. (Age 49)
Chief Scientific Officer
Mr. Ryan Baker
Head of Investor Relations
Ms. Adi Osovsky
VP & Head of Legal
Mr. Phillipe Brantegem
Vice-President of Human Resources

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ITOS Stock Analysis - Frequently Asked Questions

Should I buy or sell iTeos Therapeutics stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iTeos Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ITOS shares.
View ITOS analyst ratings or view top-rated stocks.
What is iTeos Therapeutics' stock price target for 2024?: 3 equities research analysts have issued 12-month price objectives for iTeos Therapeutics' shares. Their ITOS share price targets range from $29.00 to $44.00. On average, they anticipate the company's stock price to reach $35.33 in the next twelve months. This suggests a possible upside of 256.9% from the stock's current price.
View analysts price targets for ITOS or view top-rated stocks among Wall Street analysts.
How have ITOS shares performed in 2023?: iTeos Therapeutics' stock was trading at $19.53 at the beginning of 2023. Since then, ITOS stock has decreased by 49.3% and is now trading at $9.90.
View the best growth stocks for 2023 here.
Are investors shorting iTeos Therapeutics?: iTeos Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 1,590,000 shares, a decrease of 9.1% from the October 31st total of 1,750,000 shares. Based on an average trading volume of 431,100 shares, the short-interest ratio is presently 3.7 days. Currently, 5.6% of the company's shares are sold short.
View iTeos Therapeutics' Short Interest.
When is iTeos Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our ITOS earnings forecast.
How were iTeos Therapeutics' earnings last quarter?: iTeos Therapeutics, Inc. (NASDAQ:ITOS) posted its earnings results on Tuesday, November, 7th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.20) by $0.30. iTeos Therapeutics had a net margin of 9.02% and a negative trailing twelve-month return on equity of 9.72%.

What ETFs hold iTeos Therapeutics' stock?: ETFs with the largest weight of iTeos Therapeutics (NASDAQ:ITOS) stock in their portfolio include Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).
What other stocks do shareholders of iTeos Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other iTeos Therapeutics investors own include Advanced Micro Devices (AMD), GW Pharmaceuticals (GWPH), Trevena (TRVN), Blink Charging (BLNK), Chegg (CHGG), Centene (CNC), Datadog (DDOG), Global Blood Therapeutics (GBT) and Genocea Biosciences (GNCA).
When did iTeos Therapeutics IPO?: (ITOS) raised $151 million in an IPO on Friday, July 24th 2020. The company issued 8,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are iTeos Therapeutics' major shareholders?: iTeos Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include 683 Capital Management LLC (2.26%), Deerfield Management Company L.P. Series C (2.02%), Jacobs Levy Equity Management Inc. (1.28%), Barclays PLC (0.90%), Bank of New York Mellon Corp (0.78%) and Northern Trust Corp (0.77%). Insiders that own company stock include Aaron I Davis, Ansbert Gadicke, Bioventures 2014 LP Mpm, Bioventures 2018 LP Mpm, Boxer Capital, Llc, David Hallal, Detlev Biniszkiewicz, Joanne Jenkins Lager, Les B Korsh, Matthew Gall, Michel Detheux and Yvonne Mcgrath.
View institutional ownership trends.
How do I buy shares of iTeos Therapeutics?: Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ITOS) was last updated on 12/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial